-
Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations
•
Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation of a joint venture named Sagesse Bio, Inc. with US investment firm Gore Range Capital. This strategic partnership is complemented by a patent transfer and license agreement that will see Sirnaomics transferring specific intellectual property…
-
Sirnaomics’ STP122G Achieves Phase I Milestone with Positive Interim Data for Anticoagulation Treatment
•
Sirnaomics Ltd (HKG: 2257) has announced the completion of the Phase I second sequence for its drug candidate STP122G, which is being developed as an anticoagulation treatment, along with the release of interim data. The Factor XI program, to which STP122G belongs, has broad therapeutic potential as an anticoagulant across…
-
Sirnaomics’ STP707 Shows Promising Results in Phase I Pancreatic Cancer Trial
•
Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company, has announced the successful completion of a Phase I clinical study for its small interfering RNA (siRNA) drug candidate, STP707, which has shown good safety and preliminary signs of activity in pancreatic cancer. The dose-escalation study was conducted across 11 cancer clinics in…
-
Sirnaomics Partners with Hualan Biological to Develop and Commercialize RSV mRNA Vaccine in China
•
Sirnaomics Ltd (HKG: 2257) has entered into a strategic partnership with China’s Hualan Biological Engineering Inc., (SHE: 002007), to enhance the clinical development and commercialization of Sirnaomics’ respiratory syncytial virus (RSV) mRNA vaccine, RV-1770, in China. Under the agreement, Hualan will oversee clinical development, industrialization, and commercialization of the vaccine…
-
Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment
•
Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of RNAi therapeutics, has announced receiving a written response from the U.S. Food and Drug Administration (FDA) regarding the required Class C meeting for STP705, a treatment for in situ squamous cell carcinoma (isSCC). The Class…
-
Sirnaomics Ltd Granted FDA Approval for Phase I RSV mRNA Vaccine Study
•
Sirnaomics Ltd (HKG: 2257) has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical study for its mRNA vaccine candidate RV-1770, targeting the respiratory syncytial virus (RSV) to prevent infections in adults. The study will involve the administration of three different doses (50mg,…
-
Sirnaomics’ STP705 Demonstrates Positive Results in Phase I Focal Fat Reduction Study
•
Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I clinical study for its investigational product, STP705, which is focused on focal fat reduction (FFR). The study provides valuable insights into the potential of STP705 as a non-invasive treatment for reducing fat accumulation in specific…
-
Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation
•
The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements with AstraZeneca (AZ, NASDAQ: AZN), Tigermed (SHE: 300347), Simcere (HKG: 2096), and a total of 20 other companies. This initiative is set to generate cumulative investments of HKD 30 billion (approximately USD 3.83 billion) in…
-
Sirnaomics’ STP707 siRNA Drug Shows Promising Results in Phase I Solid Tumor Study
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has revealed that all patients have been dosed in a Phase I clinical study for its siRNA drug candidate STP707, which targets multiple solid tumors. The study is designed to assess the safety, tolerability, and anti-tumor activity of STP707 in six dose…
-
Sirnaomics Ltd Partners with Edirna Inc. to Advance RNA Editing Therapy
•
Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced a strategic partnership with US-based Edirna Inc., a newly launched biotech startup focused on RNA editing therapy. Funding and Licensing Agreement DetailsUnder the terms of the agreement, Sirnaomics is providing start-up funding to support Edirna’s…
-
Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G
•
Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical trial for its leading RNAi drug candidate, STP122G, an anticoagulation treatment. STP122G, developed using Sirnaomics’ GalNAc RNAi delivery platform technology GalAhead, targets Factor XI and has broad applicability across various disease indications, including the potential…
-
Sirnaomics’ RV-1730 Receives FDA Clearance for Phase I COVID-19 Vaccine Booster Trial
•
Sirnaomics Ltd (HKG: 2257) has announced that it has received clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for a Phase I clinical trial of RV-1730, a SARS-CoV-2 vaccine booster candidate. Design of the Phase I Study for RV-1730The Phase I…
-
Sirnaomics Commences Phase I Clinical Trial for Factor Xl RNAi Drug STP122G
•
Sirnaomics Ltd (HKG: 2257) has announced the commencement of a single-center, randomized, double-blind, placebo-controlled, sequence grouping Phase I clinical study for its factor Xl-targeted RNAi drug, STP122G. The US-based trial is designed to assess the safety, tolerability, and pharmacokinetics of the drug in healthy subjects initially, before expanding to its…
-
Sirnaomics Accelerates STP705 Development After Positive Skin Cancer Trial Results
•
Sirnaomics Ltd (HKG: 2257) is advancing the clinical development of STP705 following positive results from a Phase IIb study in cutaneous squamous cell carcinoma in situ (isSCC) and a Phase II study in basal cell carcinoma (BCC). The company is actively engaging with the US FDA to finalize the protocol,…
-
Sirnaomics’ Lead Candidate STP707 Shows Promising Phase I Data
•
Sino-US small interfering RNA (siRNA) specialist Sirnaomics (HKG: 2257) has revealed that its lead pipeline candidate STP707 has produced strong early safety and efficacy data in a Phase I clinical trial. STP707, which is comprised of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA and formulated in a peptide nanoparticle…
-
Sirnaomics Announces Interim Results for STP705 in Phase IIb Study for isSCC
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part one of a Phase IIb clinical study for STP705, a therapeutic that combines TGF-β1/COX-2 with histidine-lysine polypeptide (siRNA/HKP) nanoparticle silencing. The trial is assessing the therapy as a treatment for cutaneous squamous cell carcinoma in…
-
Innoforce Partners with RNAimmune for mRNA Development and Production
•
Hangzhou-based biopharma partner company Innoforce Pharmaceuticals Co., Ltd struck a partnership with RNAimmune, a spin-off from Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257). The former will provide the latter with services including DNA plasmid preparation, research into mRNA IVT stock solution technology, development of lipid nanoparticle (LNP) encapsulation process,…
-
Sirnaomics Announces Key Executive Promotions Effective November 15
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced key changes to its C-suite, effective as of November 15, 2022. These leadership moves reflect the company’s strategic focus on growth and operational excellence. CFO PromotionYe Yongji, former China Chief Financial Officer (CFO), has been promoted to group CFO, vice-president…
-
Sirnaomics Initiates Phase I Study of STP705 for Abdominal Fat Reduction
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the first subject dosing in a Phase I clinical study for its STP705, targeting adult abdominal fat reduction. The study, expected to report results during the first half of 2023, marks a significant step forward in the development of non-invasive…
-
Sirnaomics’ STP705 Achieves 100% Complete Remission in Basal Cell Carcinoma Study
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced positive results from a Phase II study of STP705 for basal cell carcinoma (BCC). The open-label, dosage escalation trial showed 100% complete remission (CR) in the 180 μg dose cohort, with stable or improved cosmetic outcomes in all subjects. The treatment…
